Skip to main content
Clinical Trials/NCT05578001
NCT05578001Active, not recruitingPhase 3

Efficacy of Pilocarpine 1% in Pseudophakia Individuals With Presbyopia

Isfahan University of Medical Sciences1 site in 1 country25 target enrollmentStarted: July 1, 2022Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Active, not recruiting
Enrollment
25
Locations
1
Primary Endpoint
Best Corrected Near Visual Acuity

Study Overview

Brief Summary

In this before-after interventional study on patients with presbyopia after cataract surgery, uncorrected distance vision and corrected distance visual acuity are measured and recorded by Snellen chart. Corrected near visual acuity from a distance of 40 cm is measured by the standard near vision chart (Rosenbaum near vision card). Twenty minutes after the administration of pilocarpine 1%, the corrected near and far visual acuity is measured again. Also, the relationship between the difference in average near visual acuity after the administration of 1% pilocarpine in pseudophakic people is measured with iris color and pupil size.

Detailed Description

After selecting the study cases, the pupil size in both photopic and scotopic conditions and iris color(based on Simionescu's classification) will be recorded. Uncorrected distance visual acuity(UCDVA) will be measured by Snellen chart. Then the appropriate glasses will be placed according to the person's refraction and the corrected distance visual acuity(BCDVA) will be measured. Without changing the fitted glasses, corrected near visual acuity(BCNVA) is measured from a distance of 40 cm by the standard near vision chart (Rosenbaum near vision card). After this stage, one drop of pilocarpine 1% is prescribed in the patient's eye and 20 minutes later, the corrected near and far visual acuity is measured again. Thirty minutes and 8 hours after the administration of pilocarpine drop, the side effects of the drug, including headache, eye pain, eye redness, eye irritation, tearing, and blurred vision at night, are checked.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
40 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Informed consent to participate in the study
  • Previous uncomplicated cartaract surgery and PCIOL insertion
  • BCDVA eqaul to or more than 8/10
  • Less than 1.5 diopter cylindrical refractive error
  • Spherical refractive error between -0.5_+1.5
  • No history of previous eye disease
  • Not using drugs that interact with pilocarpine

Exclusion Criteria

  • Occurrence of any drug-related complications
  • Unable to follow up the patient after prescribing the drug

Arms & Interventions

Pilocarpine

Experimental

1 drop of Pilocarpine 1% instill in the eye

Intervention: Pilocarpine Ophthalmic (Drug)

Outcomes

Primary Outcomes

Best Corrected Near Visual Acuity

Time Frame: 20 minutes

Comparison of the BCNVA before and after instillation of Pilocarpine 1%

Secondary Outcomes

  • Best Corrected Distance Visual Acuity(20 minutes)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Alireza Peyman

Dr. Alireza Peyman

Isfahan University of Medical Sciences

Study Sites (1)

Loading locations...

Similar Trials